Drugs that didn't show up at the EULAR 2013 Meeting in Madrid

Prior to the EULAR 2013 Meeting in Madrid I had published my list of topics, I'm interested in. I was just going through my list and found out that there are a lot of drugs that didn't have any publication at the EULAR 2013. It may mean that these drugs won't be studied anymore because the drug companies don't see any profit. But this can't be 100%, maybe some drugs need more time for the next publications.

ARRY-371797 / ARRY-797
Nothing!
Link for last ACR meeting: http://rheumatologe.blogspot.de/2012/12/arry-797-at-acr2012-in-washington.html

BT061
Nothing!
Estimated Study Completion Date: December 2013. http://clinicaltrials.gov/ct2/show/NCT01481493 So, unless there is some other information we should wait until the ACR2014.

CCX354-C
Nothing!
I'm not expecting too much in the furture.
For EULAR 2012 look at: http://rheumatologe.blogspot.de/2012/07/ccx-354-c-at-eular-2012.html

Cetrorelix
Nothing!
I have already had my reservations against this gonadotropin-releasing hormone antagonist (GnRH antagonist): http://rheumatologe.blogspot.de/2012/07/cetrorelix-at-eular-2012.html http://rheumatologe.blogspot.de/2012/12/cetrorelix-at-acr-2012-in-washington.html  

MOR103
Nothing!
After the stunt with the late breaking poster at the ACR 2013 this is disappointing, but I'd thought that the paper left open lots of questions.
Link: http://rheumatologe.blogspot.de/2012/12/mor103-at-acr-2012-in-washington.html  

NKG2a
Nothing!
Links to the previous meetings, if you're still interested: http://rheumatologe.blogspot.de/2012/07/nkg2a-nnc141-0100-at-eular-2012.html and http://rheumatologe.blogspot.de/2012/12/nkg2a-at-acr-2012-in-washington.html  

NNC0114-0005
Nothing!
NNC0114-0005 is a recombinant anti-IL-21 monoclonal antibody. I had my doubts, as one paper ended in the conclusion: "The improvements in DAS28-CRP for patients with RA at the highest dose level may suggest biologic and clinical activity of NNC0114-0005." Link: http://rheumatologe.blogspot.de/2012/12/nnc0114-0005-at-acr-2012-in-washington.html  

Ocaratuzumab
Nothing!
As ocaratuzumab showed rapid and sustained depletion of circulating B-cells in rheumatoid arthritis patients, I was surprised. Link to more information: http://rheumatologe.blogspot.de/2012/12/ocaratuzumab-at-acr-2012-in-washington.html  

Ocrelizumab
Nothing!
I didn't expect to hear more from this anti-CD20 MAB.
Link: http://rheumatologe.blogspot.de/2012/06/anti-cd-20-monoclonal-antibody.html  

Olokizumab
Nothing!
Very strange as olokizumab targets interleukin-6 (IL-6). Link to more information from the ACR 2012: http://rheumatologe.blogspot.de/2012/12/olokizumab-at-acr-2012-in-washington.html  
Postponed or abandoned?

Ozoralizumab (ATN-103)
Nothing!
It had been presented as "a trivalent, bispecific nanobody that potently neutralises TNF". Link: http://rheumatologe.blogspot.de/2012/12/ozoralizumab-atn-103-at-acr-2012-in.html
If I hear nano, I think of hype; an if new drugs don't show up at the next meeting, it makes me even more skeptical.

Pioglitazone
Nothing!
Doesn't come as a surprise, please look here:
http://rheumatologe.blogspot.de/2012/12/pioglitazone-at-acr-2012-in-washington.html 

PRTX-100 (Staphylococcal Protein A)
Nothing!
As I had been part in testing immunoadsorption, I´m not too confident in PRTX-100. But it´s still early for skepticism.You find more here: http://rheumatologe.blogspot.de/2012/12/prtx-100-staphylococcal-protein-a.html
I thought that he EULAR 2013 might still be too early. So I'll be watching, if something comes to surface at the ACR 2013.

SBI-087
Nothing!
SBI-087 is a SMIP (= small molecule immune pharmaceutical) binding to CD-20 http://rheumatologe.blogspot.de/2012/07/sbi-087-at-eular-2012.html  
Guess it's abandoned.

Synavive
Nothing!
Synavive, a combination of 2 mgs of prednisolone and 200 mgs of dipyramidole: http://rheumatologe.blogspot.de/2012/07/synavive-crx-102-at-eular-2012.html.
Should be abandoned.

Veltuzumab
Nothing!
Please check: http://rheumatologe.blogspot.de/2012/06/anti-cd-20-monoclonal-antibody.html  
A year without results? Better forget this drug.

VX-702
Nothing!
There hasn't been anything new on VX-702, a novel p38 MAPK inhibitor, since 2011. My guess: p38 MAPK inhibitors don't work.